Anna Olverling
Overview
Explore the profile of Anna Olverling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stefanitsch C, Lawrence A, Olverling A, Nilsson I, Fredriksson L
Front Cell Neurosci
. 2015 Dec;
9:456.
PMID: 26648843
The serine protease tissue-type plasminogen activator (tPA) is used as a thrombolytic agent in the management of ischemic stroke, but concerns for hemorrhagic conversion greatly limits the number of patients...
2.
Darsalia V, Olverling A, Larsson M, Mansouri S, Nathanson D, Nystrom T, et al.
Regul Pept
. 2014 May;
190-191:25-31.
PMID: 24821550
Dipeptidyl peptidase 4 (DPP-4) inhibitors are current drugs for the treatment of type 2 diabetes (T2D) based on their main property to enhance endogenous glucagon-like peptide-1 (GLP-1) levels, thus increasing...
3.
Olverling A, Huang Z, Nystrom T, Sjoholm A
Clin Sci (Lond)
. 2013 May;
125(9):433-8.
PMID: 23713675
Diabetic patients are often treated with an ACEi (angiotensin-converting enzyme inhibitor) or angiotensin receptor antagonist against hypertension or albuminuria. These drugs also have a positive impact on glucose tolerance, but...
4.
Darsalia V, Ortsater H, Olverling A, Darlof E, Wolbert P, Nystrom T, et al.
Diabetes
. 2012 Dec;
62(4):1289-96.
PMID: 23209191
Type 2 diabetes is a strong risk factor for stroke. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes. The aim of this study was...
5.
Wu L, Olverling A, Fransson L, Ortsater H, Kappe C, Gao X, et al.
Regul Pept
. 2012 May;
177(1-3):92-6.
PMID: 22587909
Liraglutide, an analog of glucagon-like peptide-1 (GLP-1), is an effective anti-diabetic agent with few side effects. Since native GLP-1 exerts vascular effects, we investigated changes in pancreatic islet blood flow...
6.
Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C, et al.
Clin Sci (Lond)
. 2011 Dec;
122(10):473-83.
PMID: 22150224
Diabetes is a strong risk factor for premature and severe stroke. The GLP-1R (glucagon-like peptide-1 receptor) agonist Ex-4 (exendin-4) is a drug for the treatment of T2D (Type 2 diabetes)...
7.
Wu L, Olverling A, Huang Z, Jansson L, Chao H, Gao X, et al.
Clin Sci (Lond)
. 2011 Nov;
122(8):375-84.
PMID: 22054347
GLP-1 (glucagon-like peptide 1) and its mimetic exendin-4 are used against Type 2 diabetes. C-peptide has also proven promising to enhance insulin action. Since insulin secretion in vivo can be...